Hetero Drugs Ltd.

It did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsyc

Gilead Sciences, Inc. ’s voluntary licensing (VL) agreements for lenacapavir may have managed to take some of the sting out of the patent opposition case in India but health groups and activists don’t

Gilead Sciences, Inc. ’s voluntary licensing (VL) agreements for lenacapavir may have managed to take some of the sting out of the patent opposition case in India but health groups and activists don’t

A panel discussion on intellectual property rights in India was marked by diverging positions and counter arguments on certain key provisions including pre-grant oppositions and restrictions on patent